417 related articles for article (PubMed ID: 7553649)
1. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
de Vries TJ; Kitson JL; Silvers WK; Mintz B
Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
[TBL] [Abstract][Full Text] [Related]
2. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
de Vries TJ; Quax PH; Denijn M; Verrijp KN; Verheijen JH; Verspaget HW; Weidle UH; Ruiter DJ; van Muijen GN
Am J Pathol; 1994 Jan; 144(1):70-81. PubMed ID: 8291613
[TBL] [Abstract][Full Text] [Related]
4. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
Robert C; Bolon I; Gazzeri S; Veyrenc S; Brambilla C; Brambilla E
Clin Cancer Res; 1999 Aug; 5(8):2094-102. PubMed ID: 10473092
[TBL] [Abstract][Full Text] [Related]
5. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Shapiro RL; Duquette JG; Roses DF; Nunes I; Harris MN; Kamino H; Wilson EL; Rifkin DB
Cancer Res; 1996 Aug; 56(15):3597-604. PubMed ID: 8758932
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
7. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
Häckel C; Czerniak B; Ayala AG; Radig K; Roessner A
Cancer; 1997 Jan; 79(1):53-8. PubMed ID: 8988726
[TBL] [Abstract][Full Text] [Related]
8. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
Umeda T; Eguchi Y; Okino K; Kodama M; Hattori T
J Pathol; 1997 Dec; 183(4):388-97. PubMed ID: 9496254
[TBL] [Abstract][Full Text] [Related]
9. Spitz naevi may express components of the plasminogen activation system.
Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ
J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068
[TBL] [Abstract][Full Text] [Related]
10. Comparative decreases in tyrosinase, TRP-1, TRP-2, and Pmel 17/silver antigenic proteins from melanotic to amelanotic stages of syngeneic mouse cutaneous melanomas and metastases.
Orlow SJ; Silvers WK; Zhou BK; Mintz B
Cancer Res; 1998 Apr; 58(7):1521-3. PubMed ID: 9537258
[TBL] [Abstract][Full Text] [Related]
11. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activation in melanocytic neoplasia.
Delbaldo C; Masouye I; Saurat JH; Vassalli JD; Sappino AP
Cancer Res; 1994 Aug; 54(16):4547-52. PubMed ID: 8044805
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
14. Regulation of plasminogen activators and type-1 plasminogen activator inhibitor by cyclic AMP and phorbol ester in rat astrocytes.
Tranque P; Robbins R; Naftolin F; Andrade-Gordon P
Glia; 1992; 6(3):163-71. PubMed ID: 1335967
[TBL] [Abstract][Full Text] [Related]
15. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
De Petro G; Tavian D; Copeta A; Portolani N; Giulini SM; Barlati S
Cancer Res; 1998 May; 58(10):2234-9. PubMed ID: 9605771
[TBL] [Abstract][Full Text] [Related]
16. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?
Camani C; Gavin O; Kruithof EK
Thromb Haemost; 2000 Feb; 83(2):290-6. PubMed ID: 10739388
[TBL] [Abstract][Full Text] [Related]
17. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
Paciucci R; Torà M; Díaz VM; Real FX
Oncogene; 1998 Feb; 16(5):625-33. PubMed ID: 9482108
[TBL] [Abstract][Full Text] [Related]
18. Cultured human mesangial cells produce both type 1 and type 2 plasminogen activator inhibitors.
Colucci M; Gesualdo L; Montemurro P; Cavallo LG; Conese M; Mascolo E; Ranieri E; Di Paolo S; Schena FP; Semeraro N
Thromb Haemost; 1995 Dec; 74(6):1516-20. PubMed ID: 8772230
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas.
Sirén V; Peltonen J; Vaheri A
Arch Dermatol Res; 2006 Mar; 297(9):421-4. PubMed ID: 16408192
[TBL] [Abstract][Full Text] [Related]
20. Fibrin induction of tissue plasminogen activator expression in corneal endothelial cells in vitro.
Ramsby ML; Kreutzer DL
Invest Ophthalmol Vis Sci; 1993 Oct; 34(11):3207-19. PubMed ID: 7691778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]